Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
AMPE > SEC Filings for AMPE > Form 8-K on 21-Mar-2014All Recent SEC Filings

Show all filings for AMPIO PHARMACEUTICALS, INC.

Form 8-K for AMPIO PHARMACEUTICALS, INC.


21-Mar-2014

Entry into a Material Definitive Agreement


Item 1.01 Entry into a Material Definitive Agreement.

On March 17, 2014, Ampio Pharmaceuticals, Inc. (the "Company") entered into an Addendum No. 4 (the "Addendum") to the Sponsored Research Agreement, dated September 1, 2009 (the "Original Agreement"), by and among the Company, Trauma Research LLC ("Trauma Research") and Luoxis Diagnostics, Inc., a subsidiary of the Company ("Luoxis"). Trauma Research is an entity controlled by our director and Chief Scientific Officer, Dr. Bar-Or. The Original Agreement expires on August 31, 2014 and is critical to the research and development activities of the Company and Luoxis as well as providing a cost efficient model for these activities. The Addendum extends the term of the Original Agreement through March 31, 2019, contains a "no termination" period through March 31, 2017 and significantly modifies and expands the research activities in support of the business plans of the Company and Luoxis. In exchange for Trauma Research extending the terms of the Original Agreement and for the expanded services, the Company and Luoxis have agreed to prepay Trauma Research in the aggregate amounts of $725,000 and $615,000, respectively, during 2014.

The foregoing description of the Addendum does not purport to be complete and is qualified in its entirety by reference to the Original Agreement, a redacted copy of which was filed as Exhibit 10.5 to Amendment No. 1 to the Company's Current Report on Form 8-K filed with the Securities Exchange Commission on March 17, 2010, and to the full text of the Addendum , which will be filed as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ending March 31, 2014. The Company intends to submit a FOIA Confidential Treatment Request to the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), requesting that it be permitted to redact certain portions of the Addendum, consistent with the redacted Original Agreement. The omitted material will be included in the request for confidential treatment.


  Add AMPE to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for AMPE - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.